Compass Therapeutics, Inc. — Director's Dealing 2020

Aug 11, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (NONE)
CIK: 0001738021
Period of Report: 2020-08-06

Reporting Person: Bisker-Leib Vered (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-06	Stock Option (Right to Buy)	$5.00	A	600000	Acquired	2030-08-06	Common Stock (600000)	Direct

Footnotes

F1: 33% of this option is immediately vested and exercisable, with the remainder vesting in 24 substantially equal monthly installments thereafter.